Efficacy and Safety of Rengalin in the Treatment of ARVI Cough in Children

NCT07171099

Status	RECRUITING
Phase	Phase 3
Sponsor	Materia Medica Holding
Enrollment	264 participants

Key Eligibility Criteria

Inclusion (5)

- Outpatients of both genders aged over 6 months and under 3 years.
- Clinically confirmed diagnosis of acute viral upper respiratory tract infections (acute pharyngitis, nasopharyngitis, tonsillitis, laryngitis, laryngotracheitis, tracheitis, acute viral respiratory infection of multiple and unspecified localization) during the epidemic growth of influenza and ARVI.
- Dry (non-productive) cough lasting at least 24 hours but not more than 72 hours.
- Total (day and night) cough severity score of 6 or more.
- Availability of a patient information sheet and an informed consent form for participation in the clinical trial signed by one of the patient's parents/adoptive parents.

Exclusion (16)

- Presence of the following diseases at the time of inclusion in the clinical trial:
- Inflammatory processes in the lower respiratory tract. 1.2 Grade III adenoid hypertrophy. 1.3 Chronic adenoiditis. 1.4 Postnasal drip syndrome. 1.5 Gastroesophageal reflux. 1.6 Bronchial asthma. 1.7 Cystic fibrosis. 1.8 Primary ciliary dyskinesia 1.9 Bronchopulmonary dysplasia 1.10 Malformations of the respiratory and ENT organs 1.11 Other chronic lung diseases. 1.12 Primary/secondary immunodeficiency. 1.13 Oncological disease of any localization.
- Suspected bacterial infection of any localization, including pneumonia, sinusitis, otitis media.
- Allergic rhinitis.
- Bronchial obstruction syndrome.

... and 11 more (see full listing online)

Locations (30 total)

Gatchina Clinical Interdistrict Hospital, Gatchina, Russia
Llc "Medlight", Kazan', Russia
Specialized Clinical Infectious Diseases Hospital, Krasnodar, Russia
... and 27 more locations